Oculis报告说,其眼病药物的2025年财政结果强劲,第二阶段试验数据良好,没有新的批准。 Oculis reported strong 2025 financial results and positive Phase 2 trial data for its eye disease drugs, with no new approvals.

Oculis报告了其第四季度和全年2025年的财务结果,突出显示了其眼科药物开发管道的持续进展。 Oculis reported its fourth-quarter and full-year 2025 financial results, highlighting continued progress in its ophthalmic drug development pipeline. 该公司注意到其主要候选人临床试验的进展,包括第二阶段研究得出的积极中期数据。 The company noted advancements in clinical trials for its lead candidates, including positive interim data from a Phase 2 study. Oculis还更新了其财务状况,表示其资金仍然充足,支持正在进行的研究和发展活动。 Oculis also updated its financial position, stating it remains well-capitalized to support ongoing research and development activities. 在此期间,没有宣布任何重大监管决定或产品批准。 No major regulatory decisions or product approvals were announced during the period.